MIT FINGERS-7B: First Multi-Omics AI Model for Alzheimer’s Prevention
Summary
MIT released FINGERS-7B, a 7-billion-parameter multi-omics foundation model trained on data from 30,000 individuals to predict Alzheimer's risk years in advance. The model is accessible via the AD Workbench and is accompanied by a research paper on OpenReview.
Similar Articles
The biggest AI breakthrough in medicine & drug discovery
MAML is a novel multi-modal AI model that unifies understanding of chemistry, genetics, and proteins, outperforming specialized models on 11 drug discovery benchmarks, promising to accelerate pharmaceutical research and improve success rates.
AlphaGenome: AI for better understanding the genome
DeepMind introduces AlphaGenome, an AI model that predicts how DNA sequence variants impact gene regulation and biological processes across diverse cell types and tissues. The model processes up to 1 million base pairs and is available via API for non-commercial research, with the full paper published in Nature.
Uncertainty-Aware Longitudinal Forecasting of Alzheimer's Disease Progression Using Deep Learning
This paper proposes a probabilistic framework for Alzheimer's disease progression forecasting that combines ordinal diagnosis prediction, multi-horizon trajectory generation, and decomposed uncertainty estimation using a Temporal Fusion Transformer encoder and an autoregressive Mixture Density Network. The model outperforms baselines on ADNI data, achieving near-nominal 90% credible interval coverage with clinically meaningful uncertainty signals.
Uniting biological toolkits for a new approach to ALS
DeepMind's Co-Scientist AI tool bridges the expertise of two researchers from different biological fields to accelerate ALS research by generating testable hypotheses and identifying RNA-based mechanisms for potential therapies.
Early Detection of Alzheimer's Disease Using Explainable Machine Learning on Clinical Biomarkers: A Multi-Class Classification Study Using the Alzheimer's Disease Neuroimaging Initiative (ADNI) Dataset
This study develops an XGBoost classifier using SHAP explainability on eight clinical biomarkers from the ADNI dataset to achieve three-class Alzheimer's disease detection (normal cognition, MCI, AD), reaching a macro AUC of 0.982 and Cohen's kappa of 0.909 on the held-out test set. SHAP analysis identifies CDR Global as the dominant predictor for NC and MCI, while CDR-SB and MMSE together drive AD classification.